Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
iCAD, Inc. stock logo
ICAD
iCAD
$1.60
+2.6%
$1.64
$1.05
$3.97
$42.46M1.34191,354 shs8,298 shs
Soliton, Inc. stock logo
SOLY
Soliton
$22.58
$21.55
$7.40
$22.60
$487.66M0.19347,827 shsN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
$4.38
-2.0%
$5.82
$4.23
$11.26
$107.97M0.95134,188 shs24,121 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.27
+0.5%
$1.25
$0.75
$7.44
$7.86M-1.114,421 shs690 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
iCAD, Inc. stock logo
ICAD
iCAD
+2.63%-2.50%-2.50%+3.31%+7.59%
Soliton, Inc. stock logo
SOLY
Soliton
0.00%0.00%0.00%0.00%0.00%
TELA Bio, Inc. stock logo
TELA
TELA Bio
-2.19%-10.06%-21.99%-36.60%-52.75%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
+0.48%-6.91%-4.27%+33.26%-69.13%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
iCAD, Inc. stock logo
ICAD
iCAD
0.2032 of 5 stars
2.03.00.00.00.00.80.0
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
1.9138 of 5 stars
3.52.00.00.02.21.70.6
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/A
iCAD, Inc. stock logo
ICAD
iCAD
N/AN/A$5.00212.50% Upside
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
3.00
Buy$13.67212.02% Upside
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A

Current Analyst Ratings

Latest GNMK, ICAD, SOLY, VAPO, and TELA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
iCAD, Inc. stock logo
ICAD
iCAD
$17.32M2.45N/AN/A$1.27 per share1.26
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A$1.46 per shareN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
$58.45M1.85N/AN/A$0.77 per share5.69
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.11N/AN/A($9.01) per share-0.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
iCAD, Inc. stock logo
ICAD
iCAD
-$4.85M-$0.22N/AN/A-27.08%-21.63%-15.22%5/20/2024 (Estimated)
Soliton, Inc. stock logo
SOLY
Soliton
-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%5/1/2024 (Estimated)

Latest GNMK, ICAD, SOLY, VAPO, and TELA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million
3/12/2024Q4 2023
iCAD, Inc. stock logo
ICAD
iCAD
N/A-$0.02-$0.02-$0.09N/A$4.74 million
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
iCAD, Inc. stock logo
ICAD
iCAD
N/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
iCAD, Inc. stock logo
ICAD
iCAD
N/A
4.40
4.26
Soliton, Inc. stock logo
SOLY
Soliton
N/A
5.47
5.37
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.15
4.23
3.45
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
iCAD, Inc. stock logo
ICAD
iCAD
24.61%
Soliton, Inc. stock logo
SOLY
Soliton
35.11%
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
iCAD, Inc. stock logo
ICAD
iCAD
11.95%
Soliton, Inc. stock logo
SOLY
Soliton
12.00%
TELA Bio, Inc. stock logo
TELA
TELA Bio
5.70%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
iCAD, Inc. stock logo
ICAD
iCAD
10826.54 million23.37 millionOptionable
Soliton, Inc. stock logo
SOLY
Soliton
1421.60 million19.01 millionNot Optionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
22724.65 million23.25 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.21 million5.23 millionNo Data

GNMK, ICAD, SOLY, VAPO, and TELA Headlines

SourceHeadline
Head to Head Comparison: Delcath Systems (NASDAQ:DCTH) vs. Vapotherm (NYSE:VAPO)Head to Head Comparison: Delcath Systems (NASDAQ:DCTH) vs. Vapotherm (NYSE:VAPO)
americanbankingnews.com - April 21 at 1:26 AM
Onymos Powers Connected Cloud App for Global Medical Technology Company, VapothermOnymos Powers Connected Cloud App for Global Medical Technology Company, Vapotherm
dbta.com - March 25 at 5:37 PM
Vapotherm to debut home ventilator to improve patient careVapotherm to debut home ventilator to improve patient care
msn.com - March 20 at 7:36 PM
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
finance.yahoo.com - March 20 at 7:36 PM
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
finance.yahoo.com - March 15 at 10:23 AM
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherms High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfortDr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
prnewswire.com - March 6 at 6:45 AM
Vapotherms HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South Americas Largest Health Care MarketVapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
prnewswire.com - February 29 at 6:45 AM
Vapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - February 23 at 7:30 AM
Vapotherm: Q4 Earnings SnapshotVapotherm: Q4 Earnings Snapshot
chron.com - February 22 at 9:28 PM
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
prnewswire.com - February 22 at 4:10 PM
Innovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market DynamicsInnovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market Dynamics
opprairie.com - February 12 at 10:06 AM
Vapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And ExhibitsVapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And Exhibits
cbonds.com - December 17 at 8:45 AM
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXOTC Markets Group Welcomes Vapotherm, Inc. to OTCQX
financialpost.com - December 15 at 7:08 AM
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
finance.yahoo.com - December 14 at 8:20 PM
Vapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting PlanVapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting Plan
marketwatch.com - December 14 at 8:20 PM
Vapotherm Shares Decline 22% on Voluntary Delisting Grom NYSEVapotherm Shares Decline 22% on Voluntary Delisting Grom NYSE
marketwatch.com - December 11 at 1:11 PM
Vapotherm slips on announcing voluntary delisting from NYSE to OTCQX MarketplaceVapotherm slips on announcing voluntary delisting from NYSE to OTCQX Marketplace
msn.com - December 11 at 8:11 AM
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
finance.yahoo.com - December 11 at 8:11 AM
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm Educates over 8,000 Clinicians in Respiratory Care Month
finance.yahoo.com - November 28 at 8:21 PM
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 2:28 PM
Vapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52MVapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52M
msn.com - November 8 at 7:38 PM
Vapotherm Reports Third Quarter 2023 Financial ResultsVapotherm Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 7:38 PM
Vapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo FinanceVapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - November 8 at 9:36 AM
Earnings Outlook For VapothermEarnings Outlook For Vapotherm
benzinga.com - November 7 at 6:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GenMark Diagnostics logo

GenMark Diagnostics

NASDAQ:GNMK
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.
iCAD logo

iCAD

NASDAQ:ICAD
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Soliton logo

Soliton

NASDAQ:SOLY
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.
TELA Bio logo

TELA Bio

NASDAQ:TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.